# Phase II Study of Regorafenib as Maintenance Therapy

> **NCT03793361** · PHASE2 · COMPLETED · sponsor: **Centre Oscar Lambret** · enrollment: 127 (actual)

## Conditions studied

- Metastatic Soft Tissue Sarcoma

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03793361
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-15
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-09-26
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03793361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03793361, "Phase II Study of Regorafenib as Maintenance Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03793361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*